Loading...
COVID-19 vaccines began to receive emergency use authorization for adults in December 2020; shortly thereafter, testing in adolescents was initiated. Now, findings are presented from a manufacturer-funded, phase 3 trial of the BNT162b2 (Pfizer-BioNTech) vaccine in more than 2200 children (age range, 12–15 years) who were not previously infected with SARS-CoV-2.
Patients were assigned randomly to two injections (21 days apart) of 30 µg of BNT162b2 vaccine or placebo. Researchers compared efficacy (lack of confirmed COVID-19 at ≥7 days after dose 2), immunogenicity (measured by geometric mean neutralizing titer), and reactogenicity between these groups and also compared reactogenicity and immunogenicity results against those in young adult par…